Biofrontera

Biofrontera Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 365.96. In the previous year, Cash Conversion Cycle (CCC) was 798.20 — a change of -54.15% (lower).

Cash Conversion Cycle

365.96

YoY

-54.15%

Last updated:

Cash Conversion Cycle (CCC) of Biofrontera is 2025 365.96 . Cash Conversion Cycle (CCC) of Biofrontera was 2024 798.20 . It decreases by -54.15% lower compared to the previous year.

The Biofrontera Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
112.43 EUR
Jan 1, 2019
-9.81 EUR
Jan 1, 2020
314.83 EUR
Jan 1, 2021
203.98 EUR
Jan 1, 2022
225.95 EUR
Jan 1, 2023
140.69 EUR
Jan 1, 2024
798.20 EUR
Jan 1, 2025
365.96 EUR
The Biofrontera Cash Conversion Cycle history
YEARCash Conversion CycleYoY
365.96-54.15%
798.20+467.34%
140.69-37.73%
225.95+10.77%
203.98-35.21%
314.83-3,309.90%
-9.81-108.72%
112.43-80.06%
563.78+64.31%
343.11+136.92%
144.82+3.99%
139.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Cash Conversion Cycle (CCC) of Biofrontera is 365.96 in 2025.

Cash Conversion Cycle (CCC) of Biofrontera changed from 798.20 to 365.96, representing a -54.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biofrontera

All Key Metrics — Biofrontera